Mucormycosis: Black Devious Wanderer
Sindhu Ravindra1, Karthik D Yadav2*, Praveen Kumar Varma3, Chritson4 and Sindhe J Raghunand5
1Senior Lecturer, Department of Oral Medicine and Radiology, The Oxford Dental College, Bangalore, India
2Senior Lecturer, Department of Oral Medicine and Radiology, K.G.F College of Dental Sciences and Dental Enclave, Bangalore, India
3Professor, Department of Orthodontics, Vishnu Dental College, Vishnupur, Bhimavaram, India
4Department of Conservative and Endodontics, K.G.F College of Dental Sciences and Dental Enclave, Bangalore, India
5Senior Lecturer, Master of Dental Surgery, Department of Oral Medicine and Radiology Oxford Dental College, Bangalore, India
*Corresponding Author: Karthik D Yadav, Senior Lecturer, Department of Oral Medicine and Radiology, K.G.F College of Dental Sciences and Dental Enclave, Bangalore, India.
Received: May 19, 2021; Published: : May 26, 2021
The treatment of COVID-19 has burdened the health infrastructure to its limit and beyond. Among the various complications that are seen post COVID, mucormycosis is one of the most dangerous condition seen which has devastating effects on the already immunocompromised patient with a very poor prognosis. It would mean that the patient who might win the war against COVID-19 may lose the battle against mucormycosis. The various organs affected are dependent on the route of transmission of the virus. A well- planned approach with preventive as well as other timely management of the disease process is highly beneficial and should be done to achieve a better prognosis.
Keywords: Mucormycosis; COVID-19; Fungi; Opportunistic; Immunocompromised
- Richardson M. “The ecology of the Zygomycetes and its impact on environmental exposure”. Clinical Microbiology and Infection 5 (2009): 2-9.
- Petrikkos G., et al. “Epidemiology and clinical manifestations of mucormycosis”. Clinical Infectious Diseases 1 (2012): S23-34.
- Ribes JA., et al. “Zygomycetes in human disease”. Clinical Microbiology Reviews 13 (2000): 236-301.
- Song Y., et al. “Mucormycosis in renal transplant recipients: review of 174 reported cases”. BMC Infectious Diseases 1 (2017): 283.
- Abdalla A., et al. “Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan”. Journal of Clinical Microbiology 3 (2002): 1031-1036.
- Vallabhaneni S and Mody RK. “Gastrointestinal mucormycosis in neonates: a review”. Current Fungal Infection Reports (2015).
- Francis JR., et al. “Mucormycosis in children: review and recommendations for management”. Journal of the Pediatric Infectious Diseases Society 2 (2018): 159-164.
- Lewis RE and Kontoyiannis DP. “Epidemiology and treatment of mucormycosis”. Future Microbiology 9 (2013): 1163-1175.
- Spellberg B., et al. “Novel perspectives on mucormycosis: pathophysiology, presentation, and management”. Clinical Microbiology Reviews 3 (2005): 556-569.
- Fazel R., et al. “Exposure to low-dose ionizing radiation from medical imaging procedures”. The New England Journal of Medicine 361 (2009): 849-857.
- Mehta S and Pandey A. “Rhino-orbital mucormycosis associated with COVID-19”. Cureus9 (2020): e10726.
- Roden MM., et al. “Epidemiology and outcome of zygomycosis: a review of 929 reported cases”. Clinical Infectious Diseases5 (2005): 634-653.
- Walsh TJ., et al. “Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)”. Clinical Infectious Diseases 1 (2012): S55-60.
- Avery RK and Michaels MG. “Strategies for safe living after solid organ transplantation”. American Journal of Transplantation 4 (2013): 304-310.
- Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients”. MMWR Recommendations and Reports 49.10 (2000): 1-125.
- Davies BW., et al. “Increased incidence of rhino-orbital-cerebral mucormycosis after Colorado flooding”. Ophthalmic Plastic and Reconstructive Surgery - LWW Journals 3-1 (2017): S148-S151.
- Cornely OA., et al. “Global guideline for the diagnosis and management of mucormycosis: an initiative of the european confederation of medical mycology in cooperation with the mycoses study group education and research consortium”. The Lancet Infectious Diseases 12 (2019): e405-421.
- Muthu V., et al. “Has the mortality from pulmonary mucormycosis changed over time? a systematic review and meta-analysis”. Clinical Microbiology and Infection (2021).